The pharmacological role of P-glycoprotein in the intestinal epithelium

被引:84
作者
Van Asperen, J
Van Tellingen, O
Beijnen, JH
机构
[1] Netherlands Canc Inst, Dept Clin Chem, NL-1066 CX Amsterdam, Netherlands
[2] Slotervaart Hosp, Dept Pharm, NL-1066 EC Amsterdam, Netherlands
关键词
P-glycoprotein; intestine; oral bioavailability; reversal agents; intestinal secretion;
D O I
10.1006/phrs.1998.0326
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
P-glycoprotein, a membrane-associated transport protein, has recently been recognised as an important element of the intestinal epithelium. This paper summarises the in vivo data on the pharmacological role of intestinal P-glycoprotein. These data show that P-glycoprotein contributes to the elimination of many drugs by mediating their direct secretion from the blood into the intestinal lumen. In addition, there is also evidence that this protein can limit oral drug absorption. Hence, inhibition of intestinal P-glycoprotein, e.g. by a reversal agent like cyclosporin A, may be a promising strategy for improving the oral bioavailability of P-glycoprotein substrate drugs. Indeed, several preclinical and clinical studies have shown that coadministration of drugs with a reversal agent can substantially increase oral drug absorption. (C) 1998 The Italian Pharmacological Society.
引用
收藏
页码:429 / 435
页数:7
相关论文
共 41 条
[2]   EFFECT OF R-VERAPAMIL ON THE PHARMACOKINETICS OF PACLITAXEL IN WOMEN WITH BREAST-CANCER [J].
BERG, SL ;
TOLCHER, A ;
OSHAUGHNESSY, JA ;
DENICOFF, AM ;
NOONE, M ;
OGNIBENE, FP ;
COWAN, KH ;
BALIS, FM .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :2039-2042
[3]   ELIMINATION OF DRUGS BY PASSIVE DIFFUSION FROM BLOOD TO INTESTINAL LUMEN - FACTORS INFLUENCING NONBILIARY EXCRETION BY THE INTESTINAL-TRACT [J].
DAYTON, PG ;
ISRAILI, ZH ;
HENDERSON, JD .
DRUG METABOLISM REVIEWS, 1983, 14 (06) :1193-1206
[4]  
FEDELI L, 1989, CANCER, V64, P1805, DOI 10.1002/1097-0142(19891101)64:9<1805::AID-CNCR2820640908>3.0.CO
[5]  
2-D
[6]   Tacrolimus oral bioavailability doubles with coadministration of ketoconazole [J].
Floren, LC ;
Bekersky, I ;
Benet, LZ ;
Mekki, Q ;
Dressler, D ;
Lee, JW ;
Roberts, JP ;
Hebert, MF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (01) :41-49
[7]  
FORD JM, 1990, PHARMACOL REV, V42, P155
[8]   Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: In vitro in vivo correlation [J].
Fricker, G ;
Drewe, J ;
Huwyler, J ;
Gutmann, H ;
Beglinger, C .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (07) :1841-1847
[9]   Applications of the Caco-2 model in the design and development of orally active drugs: Elucidation of biochemical and physical barriers posed by the intestinal epithelium [J].
Gan, LSL ;
Thakker, DR .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 23 (1-3) :77-98
[10]   ELIMINATION OF DRUGS BY ACTIVE INTESTINAL TRANSPORT [J].
GEORGE, CF ;
GRUCHY, BS .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1979, 31 (09) :643-644